Phase 1 Study to Assess Safety and Efficacy of ANG003
Status:
Recruiting
Trial end date:
2024-06-24
Target enrollment:
Participant gender:
Summary
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered
ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic
insufficiency. The study's overall objectives are to evaluate the safety, tolerability and
effect of four dose levels of ANG003.